Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

ErbB3, a member of the ErbB family of receptor tyrosine kinases, is a potent activator of phosphatidyl inositol-3 kinase (PI3K) and mTOR signaling, driving tumor cell survival and therapeutic resistance in breast cancers. In luminal breast cancers, ErbB3 upregulation following treatment with the ant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Morrison, Meghan M., Williams, Michelle M., Vaught, David B., Hicks, Donna, Lim, Jiyeon, McKernan, Courtney, Aurisicchio, Luigi, Cennaro, Gilberto, Simion, Catalina, Sweeney, Colleen, Cook, Rebecca S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4703573/
https://ncbi.nlm.nih.gov/pubmed/26148232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.169
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados